These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25615615)

  • 1. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
    Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
    PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
    Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
    Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
    Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
    J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
    Seiboldt T; Zeiser C; Nguyen D; Celikyürekli S; Herter S; Najafi S; Stroh-Dege A; Meulenbroeks C; Mack N; Salem-Altintas R; Westermann F; Schlesner M; Milde T; Kool M; Holland-Letz T; Vogler M; Peterziel H; Witt O; Oehme I
    Br J Cancer; 2024 Sep; 131(4):763-777. PubMed ID: 38942989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
    Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
    J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
    Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
    Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer.
    Zhang GQ; Xi C; Ju NT; Shen CT; Qiu ZL; Song HJ; Luo QY
    J Endocrinol Invest; 2024 Aug; 47(8):1953-1969. PubMed ID: 38386265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
    Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
    Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.
    Klenke S; Akdeli N; Stelmach P; Heukamp L; Schulte JH; Bachmann HS
    BMC Cancer; 2019 Mar; 19(1):243. PubMed ID: 30885150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kang M; Reynolds CP; Billups CA; Favours E; Payne-Turner D; Tucker C; Smith MA
    Pediatr Blood Cancer; 2010 Dec; 55(6):1224-6. PubMed ID: 20979180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.
    Qing G; Li B; Vu A; Skuli N; Walton ZE; Liu X; Mayes PA; Wise DR; Thompson CB; Maris JM; Hogarty MD; Simon MC
    Cancer Cell; 2012 Nov; 22(5):631-44. PubMed ID: 23153536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
    Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
    PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
    Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
    Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.